Generic Name: tropifexor
Drug Class: NAFLD/NASH Medications
Approval Status: Experimental
Generic Version Available: No
Experimental Code: LJN452
Tropifexor is a farnesoid X receptor (FXR) agonist In Phase 2 clinical trials. In these trials, Novartis teamed up with Pfizer, combining various Pfizer compounds with tropifexor. These additional compounds include acetyl CoA-carboxylase (ACC) inhibitor (PF-05221304), a diacylglycerol O-acyltransferase 2 (DGAT2) inhibitor (PF-06865571, and a ketohexokinase (KHK) Inhibitor (PF-06835919).
Dosing Info: N/A
Last Reviewed: February 4, 2019